DZ Bank’s Enanta Pharmaceuticals ENTA Stock Holding History

DZ Bank’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,445	Closed	-$44K	–	956
2017 Q1	$44K	Hold	1,445	–	–	﹤0.01%	853
2016 Q4	$48K	Buy	+1,445	New	+$41.4K	﹤0.01%	810

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

DZ Bank's ENTA Position: Q2 2017 in Review

DZ Bank sold out of Enanta Pharmaceuticals (ENTA) in Q2 2017, closing a stake of 1,445 shares — an estimated $44K sold.

DZ Bank first reported a position in ENTA in Q4 2016 and held it in 2 quarters. The position peaked at $48K in Q4 2016. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2017.

DZ Bank reported no remaining Enanta Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
DZ Bank sold 1,445 Enanta Pharmaceuticals shares in Q2 2017, an estimated $44K.
DZ Bank first reported a position in Enanta Pharmaceuticals in Q4 2016 and held it in 2 quarters.
DZ Bank's Enanta Pharmaceuticals position peaked at $48K in Q4 2016.
122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2017.

Based on DZ Bank's 13F filing for Q2 2017, filed 14 Aug 2017.